A yearly injection such as Lenacapavir could help overcome barriers to PrEP accessibility by increasing its uptake and making ...
Pre-exposure prophylaxis (PrEP) is the advent of antiretroviral treatment use for people at increased risk of acquiring HIV-1 ...
A once-yearly intramuscular lenacapavir (Sunlenca) injection was safe and well-tolerated and had higher median levels of ...
Cabotegravir was found to prevent HIV acquisition as a monotherapy pre-exposure prophylaxis (PrEP) and to treat HIV as a ...
Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...
March is a significant month for women's health, observing International Women's Day and National Women's HIV/AIDS Awareness ...
Like most prescribed medications, all three brands PrEP brands feature side effects. Here's how to prepare for them.
Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...
An end-to-end digital PrEP pathway appeared to improve accessibility, inclusivity, and service satisfaction among LGBTQ+ ...